Short description
Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients.
Description
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions.
Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.
Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Tarrytown, New York, United States, North America
Founded on
January 1, 1988
Exited on
November 19, 1997
Went public on
November 19, 1997
Stock symbol
PGNX
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$34056 - 789030
Sign in for full access
Founders
Paul J. Maddon